GAINESVILLE, Fla., Oct. 11, 2011 (GLOBE NEWSWIRE) -- Quick-Med Technologies, Inc. (OTCQB:QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that company researchers have demonstrated that NIMBUS antimicrobial technology utilized in BIOGUARD Barrier Dressings offers clinicians more therapeutic flexibility than the PHMB-based antimicrobial used in Kerlix® AMD Dressings.
In vitro studies found that BIOGUARD wound dressing are completely compatible with SANTYL®, a frequently used collagenase debriding agent, while Kerlix AMD actually deactivates SANTYL'S active ingredient. The researchers also found that BIOGUARD can be used without complications with Dakin's Solution®, a popular wound cleanser based on hypochlorite, while dressings with PHMB such as Kerlix® AMD should not be used because hypochlorite deactivates the active antimicrobial agent polyhexamethylene biguanide.
These studies demonstrate the benefit of BIOGUARD over Kerlix® AMD when used with some commonly used wound treatments. As explained by Gregory Schultz, PhD, University of Florida Research Foundation Professor and past president of the Wound Healing Society, "wound care clinicians need to understand that some combinations of wound dressings and treatments can destructively interact, reducing their effectiveness, while other combinations are potentially helpful."
"BIOGUARD dressings with NIMBUS antimicrobial technology offer superior versatility and have been designed to allow worry-free use in the increasingly complex wound care environment," said Albina Mikhaylova, PhD, Senior Scientist at Quick-Med Technologies. She explained "NIMBUS is an important antimicrobial technology for medical devices because it doesn't leach or suffer depletion, doesn't initiate bacterial resistance, doesn't interfere with tissue healing, and prevents odor generation."
BIOGUARD® bacterial barrier wound dressings are marketed under license from Quick-Med by Derma Sciences, Inc. (Nasdaq:DSCI).
The study results are summarized in a new paper entitled "The Effects of BIOGUARD vs. Kerlix AMD Dressings when used in combination with Dakin's Solution or SANTYL Ointment." A copy of the paper can be downloaded at:
Quick-Med's patented technology, NIMBUS, is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS received De Novo clearance from the U.S. Food and Drug Administration and has been commercialized in traditional wound care applications. It is the only non-leaching antimicrobial dressing and, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by ten U.S. patents and patents pending and 24 foreign counterparts. Additional applications under development include advanced wound dressings, medical adhesives, and catheters.
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the consumer and healthcare markets. The Company is developing advanced antimicrobial technologies for infection prevention and control. Its NIMBUS® technology is the first FDA-cleared, non-leaching antimicrobial available in a wound dressing. Its NimbuDerm™ technology is being developed as a persistent hand sanitizer and its new Stay Fresh® technology provides highly durable antimicrobial protection for apparel and other textile applications. For more information, see: www.quickmedtech.com.
© 2011 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® and Stay Fresh® are registered trademarks and NimbuDerm™ is a trademark of Quick-Med Technologies, Inc. All other trademarks are property of their respective owners.
The Quick-Med Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8260
Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.
CONTACT: Quick-Med Technologies, Inc.
J. Ladd Greeno, CEO
(888) 835.2211 Ext 102
Stonegate Securities, Inc.
Casey Stegman (investor/media contact)